Management of mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin

Medical Journal of Australia

Volumn 189, Issue 9, 2008, Pages 532-533

  Dossou, Ange D ^a   Sopoh, Ghislain E ^a   Johnson, Christian R ^b   Barogui, Yves T ^a   Affolabi, Dissou ^c   Anagonou, Sévérin Y ^c   Zohoun, Théophile ^d   Portaels, Françoise ^e   Asiedu, Kingsley ^f  

^a Centre de Dépistage et de Traitemente de l'Ulcère   (Benin)

^b Programme national de lutte contre la lèpre   (Benin)

^c Laboratoire de Référence des Mycobactéries   (Benin)

^d UNIVERSITY OF ABOMEY CALAVI   (Benin)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; RIFAMPICIN;

ACID FAST BACTERIUM; ANAMNESIS; BURULI ULCER; CASE REPORT; DOSE RESPONSE; DRUG CONTRAINDICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREGNANT WOMAN; PUNCH BIOPSY; SKIN GRAFT; STAINING; TREATMENT DURATION; WOUND HEALING;

EID: 56749155637     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02166.x     Document Type: Letter

References (5)

1. Portaels F, Johnson F, Meyers WM, editors. Buruli ulcer. Diagnosis of Mycobacterium ulcerans disease. A manual for health care providers. Geneva: World Health Organization, 2001: 92.
2. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: WHO/CDS/CPE/GBUI.10, 2004. http://www.who.int/ buruli/information/antibiotics/en/index.html (accessed 2004).
3. Johnson PDR, Hayman JA, Quek TY et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68.
4. Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 1998; 42: 2070-2073.
5. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007; 51: 3737-3739.